Enhancement by dexamethasone of the therapeutic benefits of cisplatin via regulation of tumor angiogenesis and cell cycle kinetics in a murine tumor paradigm

Toxicology

Volumn 222, Issue 1-2, 2006, Pages 103-113

  Arafa, Hossam M M ^a   Abdel Hamid, Mostafa A ^b   El Khouly, Abeer A K ^b   Elmazar, Mohamed M A ^b   Osman, Abdel Moneim M ^c  

^a Al Azhar University   (Egypt)

^b HELWAN UNIVERSITY   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Angiogenesis; Anti tumor; Cell cycle; Cisplatin; Dexamethasone; Flowcytometry; Nephrotoxicity

Indexed keywords

CISPLATIN; DEXAMETHASONE; GLUCOCORTICOID;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; EHRLICH ASCITES TUMOR; EHRLICH ASCITES TUMOR CELL; FEMALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD UREA NITROGEN; CARCINOMA, EHRLICH TUMOR; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; CREATININE; DEXAMETHASONE; FEMALE; GLUTATHIONE; KIDNEY; MALONDIALDEHYDE; MICE; NEOVASCULARIZATION, PATHOLOGIC; TUMOR BURDEN;

ANIMALIA; MURINAE;

EID: 33646264532     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2006.02.007     Document Type: Article

References (49)

1. Aapro M.S., Alberts D.S., and Serokman R. Lack of dexamethasone effect on the antitumor activity of cisplatin. Cancer Treat. Rep. 67 (1983) 1013-1017
2. Ajith T.A., and Janardhanan K.K. Cytotoxic and antitumor activities of a polypore macrofungus, Phellinus rimosus (Berk) Pilat. J. Ethnopharmacol. 84 2-3 (2003) 157-162
3. Ajith T.A., Jose N., and Janardhanan K.K. Amelioration of cisplatin-induced nephrotoxicity in mice by ethyl acetate extract of a polypore fungus, Phellinus rimosus. J. Exp. Clin. Cancer Res. 21 (2002) 213-217
4. Attia M.A., and Weiss D.W. Immunology of spontaneous mammary carcinomas in mice. Cancer Res. 26 (1966) 1787-1800
5. Badary O.A., Sharaby S.M., Kenawy S.A., El-Denshary E.E., and Hamada F.M. Evaluation of cisplatin combined with ondansetron in Ehrlich ascites carcinoma in vitro and in vivo. Tumori 86 2 (2000) 153-156
6. Baetz T., Belch A., Couban S., Imrie K., Yau J., Myers R., Ding K., Paul N., Shepherd L., Iglesias J., Meyer R., and Crump M. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann. Oncol. 14 12 (2003) 1762-1767
7. Bespalov V.G., Aleksandrov V.A., Troian D.N., and Lidak M.I. The inhibiting effect of ortofen and dexamethasone on the development of tumors of the cervix, uteri and vagina. Farmakol. Toksikol. 53 (1990) 49-51
8. Biagi J.J., Herbert K.E., Smith C., Abdi E., Leahy M., Falkson C., Wolf M., Januszewicz H., Seymour J.F., Richards K., Matthews J.P., Dale B., and Prince H.M. A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. Leuk. Lymphoma 46 2 (2005) 197-206
9. Borjeson S., Hursti T.J., Tishelman C., Peterson C., and Steineck G. Treatment of nausea and emesis during cancer chemotherapy. Discrepancies between antiemetic effect and well-being. J. Pain Symptom Manage. 324 (2002) 345-358
10. Cha H.H., Cram E.J., Wang E.C., Huang A.J., Kasler H.G., and Firestone G.L. Glucocorticoids stimulate p21 gene expression by targeting multiple transcriptional elements within a steroid responsive region of the p21 waf1/cip1 promotor in rat hepatoma cells. J. Biol. Chem. 273 (1998) 1998-2007
11. Chrousos G.P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N. Engl. J. Med. 332 (1995) 1351-1362
12. Daniel T.O., Liu H., Morrow J.D., Crews B.C., and Manett L.J. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. 59 (1999) 4574-4577
13. Decatris M.P., Sundar S., and O'Byrne K.J. Platinum-based chemotherapy in metastatic breast cancer: The leicester (U.K.) experience. Clin. Oncol. 17 4 (2005) 249-257
14. De-Reuck J., Vandekerchove T., Bosma G., De Meulemeester K., Van Landegem W., De Waele J., Tack E., and De Koninck J. Steroid treatment in acute ischemia stroke. A comparative retrospective study of 556 cases. Eur. Neurol. 28 (1988) 70-72
15. El-Alaoui S., Lawry J., and Griffin M. The cell cycle and induction of apoptosis in a hamster fibrosarcoma cell line treated with anticancer drugs: Its importance to solid tumor chemotherapy. J. Neurooncol. 31 (1997) 195-207
16. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 74 (1959) 214
17. Evans D.L., and Dive C. Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and noproliferating immature thymocytes. Cancer Res. 53 (1993) 2133-2139
18. Fabinay D.L., and Eringhausen G. Automated reaction-rate method for the determination of serum creatinine with the centrichem. Clin. Chem. 17 (1971) 696-700
19. Hanigan M.H., Lykissa E.D., Towensend D.M., Ou C.N., Barrios R., and Lieberman M.W. Gamma-glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin. Am. J. Physiol. 159 (2001) 1889-1894
20. Hesketh P.J. Understanding the pathobiology of chemotherapy-induced nausea and vomiting. Providing a basis for therapeutic progress. Oncology 18 10 Suppl 6 (2004) 9-14
21. Hunneyball I.M., Crossley M.J., and Spowage M. Pharmacological studies of antigen-induced arthritis in BALB/c mice. Characterization of arthritis and the effects of steroidal and non-steroidal anti-inflammatory agents. Agents Actions 18 (1986) 384-393
22. Jarden J.O., Dhawan V., Moeller J.R., Strother S.C., and Rottenberg D.A. The time course of steroid action on blood to brain and blood to tumor transport of 82RB: a positron emission tomographic study. Ann. Neurol. 25 (1989) 239-245
23. Jones M.K., Wang H., Peskar B.M., Levin E., Itani R.M., Sarfeh I.J., and Tarnawski A.S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 5 (1999) 1418-1423
24. Kimura M., Suzuki J., Amemiya K., and Yamada T. Involvement of glucocorticoid in insulin-induced angiogenesis of adjuvant pouch granuloma in diabetic mice. J. Pharmacobiodyn. 10 (1987) 266-271
25. Lee K., Erturk E., Mayer R., and Cockett A.T.K. Efficacy of antitumor chemotherapy in C3H mice enhanced by the antiangiogenesis steroid, cortisone acetate. Cancer Res. 47 (1987) 5021-5024
26. Lee K., Iwamura M., and Cockett A.T.K. Cortisone inhibition of tumor angiogenesis measured by quantitative colorimetric assay in mice. Cancer Chemother. Pharmacol. 26 (1990) 461-463
27. MacDonald R.G., and Cidlowski J.A. Glucocorticoids inhibit precursor incorporation into protein in splenic lymphocytes by stimulating protein degradation and expanding intracellular amino acid pools. Biochem. Biophys. Acta 717 (1982) 236-247
28. Moore B.B., Keane M.P., Addison C.L., Arenberg D.A., and Strieter R.M. CXC chemokine modulation of angiogenesis: The importance of balance between angiogenic and angiostatic members of the family. J. Invest. Med. 46 (1998) 113-120
29. Nakamura O., Ueki K., Hibi T., Shitara N., Matsutani M., Takakura K., and Oikawa T. Inhibition of neovascularization and tumor growth by dexamethasone. No To Shinkel 44 (1992) 37-41
30. Osman A.M., El-Sayed E.M., El-Demerdash E., Al Hyder A., El Didi M., Attia A.S., and Hamada F.M. Prevention of cisplatin-induced nephrotoxicity by methimazole. Pharmacol. Res. 41 (2000) 115-121
31. Osman A.M., Jansen P.W., Smets L.A., and Benckhuijsen C. Glucocorticoid receptors and cell cycle progression in human melanoma cell lines. J. Cell Physiol. 125 (1985) 306-312
32. Patton C.J., and Crouch S.R. Spectrophotometric and kinetic investigation of the Berthelot reaction for the determination of ammonia. Anal. Chem. 49 (1977) 464-469
33. Petrie A. Lecture Notes on Medical Statistics (1987), Blackwell Year Book Medical Publishers, Inc. p. 157
34. Reisman D., and Thompson E.A. Glucocorticoid regulation of cyclin D3 gene transcription and mRNA stability in lymphoid cells. Mol. Endocrinol. 9 (1995) 1500-1509
35. Rose A.L., Smith B.E., and Maloney D.G. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 100 (2002) 1765-1773
36. Schiller J.H., and Bittner G. Potentiation of platinum antitumor effects in human lung tumor xenographts by the angiogenesis inhibitor squalamine: effects on tumor neaovascularization. Clin. Cancer Res. 5 (1999) 4287-4294
37. Shishido T., Yassoshima T., Denno R., Mukaiya M., Sato N., and Hirata K. Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin. Jpn. J. Cancer Res. 89 (1998) 963-969
38. Smets L.A., Bout B., Brouwer M., and Tulp A. Cytotoxic effects of dexamrthasone restricted to noncycling, early, G1-phase cells of L1210 leukemia. J. Cell Physiol. 116 (1983) 397-403
39. Smets L.A., and Van den Berg J.D. Bcl-2 expression and glucocorticoid-induced apoptosis of leukemic and lymphoma cells. Leuk. Lymphoma 20 (1996) 199-205
40. Taguchi T., Nazneen A., Abid M.R., and Razzaque M.S. Cisplatin-associated nephrotoxicity and pathological events. Contrib. Nephrol. 148 (2005) 107-121
41. Teicher B.A., Sotomayor E.A., and Huang Z.D. Antiangiogenic agents potentiate cytotoxic cancer chemotherapies against primary and metastatic disease. Cancer Res. 52 (1992) 6702-6704
42. Towensend D.M., Deng M., Zhang L., Lapus M.G., and Hanigan M.H. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J. Am. Soc. Nephrol. 14 (2003) 1-10
43. Uchiyama M., and Mihara M. Determination of malondialdehyde precursor in tissues by thiobarbituric acid test. Anal. Biochem. 86 (1978) 271-278
44. Viale M., Vannozzi M.O., Pastrone I., Mariggio M.A., Zicca A., Cadoni A., Cafaggi S., Tolino G., Lunardi G., Civalleri D., Lindup W.E., and Esposito M. Reduction of cisplatin nephrotoxicity by procainamide: does the formation of cisplatin-procainamide complex play a role?. J. Pharmacol. Exp. Ther. 293 (2000) 829-836
45. Vindelov L.L., Christensen I.J., Jensen G., and Nissen N.I. Limits of detection of nuclear DNA abnormalities by flowcytometric DNA analysis. Cytometry 3 (1983) 332-339
46. Wagner T., Kreft B., Bohlmann G., and Schwieder G. Effects of fosfomycin, mesna, and sodium thiosulfate on the toxicity and antitumor activity of cisplatin. J. Cancer Res. Clin. Oncol. 114 (1988) 497-501
47. Yamamoto T., Nishiguchi M., Inoue N., Goto H.G., Kudawara I., Ueda T., Yoshikawa H., Tanigaka Y., and Nishizawa Y. Inhibition of murine osteosarcoma cell proliferation by glucocorticoids. Anticancer Res. 22 (2002) 4151-4156
48. Yu W.D., McElwain M.C., modzelewski R.A., Russell D.M., Smith D.C., Trump D.L., and Johnson C.S. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J. Natl. Cancer Inst. 90 (1998) 134-141
49. Zhang L., Yang N., Garcia J.R., Mohamed A., Benecia F., Rubin S.C., Allman D., and Coukos G. Generation of a syngenic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am. J. Phathol. 161 (2002) 2295-2309